Navigation Links
Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
Date:5/16/2013

es, therapeutic proteins represent a major category of pharmaceutical products with established therapeutic value and high economic attractiveness. As more and more of the branded products are running out of patent protection and regulatory agencies are providing better guidance, development of biosimilar versions as well as of improved next generation versions are a highly attractive goal for pharmaceutical and biotechnology as well as technology focused companies.

 

This report includes a compilation of current active projects in research and development of biosimilar and novel biobetter/biosuperior therapeutic proteins as well as non-protein based competitor products and an overview of approved products in regulated and less regulated markets.

 

Competitor projects are listed in a tabular format providing Information on:

 

• Drug Codes,

• Target / Mechanism of Action,

• Class of Compound,

• Company,

• Product Category,

• Indication,

• R&D Stage and

• additional comments with a hyperlink leading to the source of information.

 

About Competitor Analysis Series:

 

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

 

 

 

Table of Contents

 

1) Erythropoiesis Stimulating Agents (ESA)

 

• First generation epoetins in regulated markets

• Second generation epoetins in regulated markets

• Epoetin biosimilars in regulated markets

• Darbepoetin biosimilars in regulated markets

• Next generation biologic Eythropoiesis Stimulating Agents (ESA) in
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cell Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
3. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Emergent Technologies and Caisson Biotech Form Strategic Alliance with Local Health Care Providers to Improve Delivery and Performance of a Therapeutic Drug
6. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
7. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
8. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
9. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
10. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
11. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Baylor Research Institute (BRI) at ... Institute (TGen) in Phoenix, AZ , ... detection and treatments for patients with a broad range of ... to new clinical trials and access to technology to drive ... bench to bedside across Baylor Scott & White ...
(Date:5/21/2015)... YORK , May 21, 2015  Prima Biomed ... company that is striving to become a leader in ... cancer, recently announced that the final CVac data from ... shown a clear trend for a clinically meaningful improvement ... in second remission patients. In the group ...
(Date:5/21/2015)... Patent Offering, The patent’s technology pertains to an ... within a body lumen (open space). Known as ... cost, single-use disposable illumination and camera module (housing). ... and the patent approval was received on January 6, ... the lighting and magnification of the endoscope for different ...
(Date:5/21/2015)... 2015 Veolia’s environmental monitoring technology ... American distribution agreement with VWR to distribute TECTA™ ... more than 160 years of experience, VWR, a ... laboratory and production facilities, has cultivated a value ... services to enable science. Endetec’s TECTA™ B16, ...
Breaking Biology Technology:Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4Correction Continues after Big Move - BrokerBank Securities, Inc. 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
... , , ROCKAWAY, N.J., Dec. ... An Evidence-Based Approach , published by the ... for anthracycline extravasation.(1) Anthracyclines are a group of chemotherapy ... used in the treatment of various types of cancer since ...
... , WALTHAM, Mass., Dec. 14 Decision ... pharmaceutical and healthcare issues, finds that, owing to the launches of ... than sevenfold from $790 million in 2008 to $6.1 billion in ... Kingdom and Japan. , The new Pharmacor report entitled Atrial ...
... SEATTLE, Dec. 11 Dendreon Corporation (Nasdaq: DNDN ) ... offering have exercised in full their option to purchase an ... price of $24.75 per share. The exercise of the ... of 17,250,000 shares of common stock. Dendreon expects to ...
Cached Biology Technology:Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2
... Applying a small mechanical force to embryonic stem ... into a specific direction of differentiation, researchers at the ... include therapeutic cloning and regenerative medicine. "Our results suggest ... inducing strong biological responses in embryonic stem cells, and ...
... A 21-year Michigan State University experiment that distills the ... natural selection at work, but could lead to ... Darwin,s seminal Origin of Species first laid out the ... professor Richard Lenski and colleagues document the process in ...
... statewide group of structural biologists with similar interests in ... on the University of Oklahoma,s Norman campus with the ... sophisticated robotics equipment. The idea for the ... facilitated a meeting among structural biologists from the OU ...
Cached Biology News:Small mechanical forces have big impact on embryonic stem cells 2Time in a bottle: Scientists watch evolution unfold 2Time in a bottle: Scientists watch evolution unfold 3